×
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
NASDAQ:ESPR

Esperion Therapeutics (ESPR) Stock Forecast, Price & News

$5.80
+0.29 (+5.26%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.38
$5.85
50-Day Range
$4.64
$6.53
52-Week Range
$3.28
$26.77
Volume
558,029 shs
Average Volume
1.33 million shs
Market Capitalization
$365.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.43
30 days | 90 days | 365 days | Advanced Chart
Receive ESPR News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Esperion Therapeutics logo

About Esperion Therapeutics

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ESPR
Fax
N/A
Employees
218
Year Founded
N/A

Sales & Book Value

Annual Sales
$78.45 million
Book Value
($3.95) per share

Profitability

Net Income
$-269.11 million
Net Margins
-263.04%
Pretax Margin
-263.04%

Debt

Price-To-Earnings

Miscellaneous

Free Float
61,495,000
Market Cap
$365.44 million
Optionable
Optionable

Company Calendar

Last Earnings
5/03/2022
Today
5/27/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.85 out of 5 stars

Medical Sector

754th out of 1,424 stocks

Pharmaceutical Preparations Industry

365th out of 681 stocks

Analyst Opinion: 3.1Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -













Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

Is Esperion Therapeutics a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 2 sell ratings, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Esperion Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View analyst ratings for Esperion Therapeutics
or view top-rated stocks.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Esperion Therapeutics
.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) released its quarterly earnings results on Tuesday, May, 3rd. The biopharmaceutical company reported ($0.93) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.11. The biopharmaceutical company earned $18.84 million during the quarter, compared to the consensus estimate of $15.41 million. The company's revenue was up 136.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($3.50) EPS.
View Esperion Therapeutics' earnings history
.

What price target have analysts set for ESPR?

8 Wall Street analysts have issued 12 month price objectives for Esperion Therapeutics' shares. Their forecasts range from $5.00 to $90.00. On average, they anticipate Esperion Therapeutics' stock price to reach $21.11 in the next twelve months. This suggests a possible upside of 264.0% from the stock's current price.
View analysts' price targets for Esperion Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Esperion Therapeutics' key executives?
Esperion Therapeutics' management team includes the following people:
  • Mr. Sheldon L. Koenig, Pres, CEO & Director (Age 56, Pay $728.91k)
  • Dr. Joanne Micale Foody FACC, M.D., Chief Medical Officer (Age 57, Pay $471.86k)
  • Dr. Kenneth J. Fiorelli, Chief Technical Operations Officer
  • Mr. Benjamin Church, Head of Corp. Communications & Investor Relations
  • Mr. Benjamin O. Looker, Gen. Counsel & Corp. Sec. (Age 40)
  • Mr. Keith F. Lenden, VP of Corp. Devel. & Strategy (Age 49)
  • Ms. Betty Jean Swartz, Chief Strategy Officer
  • Mr. Eric J. Warren R.Ph., Chief Commercial Officer (Age 49)
  • Ms. April Seiler, Sr. Director of Project Management
  • Roberta Peterson, Sr. Director of National Accounts
What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?

20 employees have rated Esperion Therapeutics CEO Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among Esperion Therapeutics' employees.

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wasatch Advisors Inc. (12.93%), Deep Track Capital LP (9.52%), Vanguard Group Inc. (7.13%), Bellevue Group AG (6.82%), Paradigm Biocapital Advisors LP (1.84%) and Rhenman & Partners Asset Management AB (1.56%). Company insiders that own Esperion Therapeutics stock include Eric Warren, Sheldon L Koenig and Target N V Biotech.
View institutional ownership trends for Esperion Therapeutics
.

Which major investors are selling Esperion Therapeutics stock?

ESPR stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, Walleye Trading LLC, State Street Corp, Monaco Asset Management SAM, PDT Partners LLC, UBS Group AG, Group One Trading L.P., and HAP Trading LLC. Company insiders that have sold Esperion Therapeutics company stock in the last year include Eric Warren, and Sheldon L Koenig.
View insider buying and selling activity for Esperion Therapeutics
or view top insider-selling stocks.

Which major investors are buying Esperion Therapeutics stock?

ESPR stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Vanguard Group Inc., Renaissance Technologies LLC, Deep Track Capital LP, Paradigm Biocapital Advisors LP, Northern Trust Corp, Bank of New York Mellon Corp, and Goldman Sachs Group Inc..
View insider buying and selling activity for Esperion Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $5.80.

How much money does Esperion Therapeutics make?

Esperion Therapeutics has a market capitalization of $365.44 million and generates $78.45 million in revenue each year. The biopharmaceutical company earns $-269.11 million in net income (profit) each year or ($6.99) on an earnings per share basis.

How many employees does Esperion Therapeutics have?

Esperion Therapeutics employs 218 workers across the globe.

What is Esperion Therapeutics' official website?

The official website for Esperion Therapeutics is www.esperion.com.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at [email protected].

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.